Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin ii type 1 receptor blockade: Are prescribed doses too low?

Hypertension

Volumn 60, Issue 2, 2012, Pages 278-280

  Leenen, Frans H H ^a,b   Ruzicka, Marcel ^c   Floras, John S ^a,c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NORADRENALIN; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; HEART FAILURE; HUMAN; HYPERTENSION; LIPOPHILICITY; MONOTHERAPY; NONHUMAN; NORADRENALIN BLOOD LEVEL; NOTE; PARAVENTRICULAR THALAMIC NUCLEUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC BLOCKING; SYMPATHETIC NERVE; SYMPATHETIC TONE; TREATMENT OUTCOME;

CHLORTHALIDONE; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; SPIRONOLACTONE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84864282906     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.197012     Document Type: Note

References (12)

1. Huang BS, Ahmadi S, Ahmad M, White RA, Leenen FHH. Central neuronal activation and pressor responses induced by circulating ANG II: role of brain aldosterone-"ouabain" pathway. Am J Physiol. 2010;299: H422-H430.
2. Xue B, Beltz TG, Yu Y, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Central interactions of aldosterone and angiotensin II in aldosteroneand angiotensin II-induced hypertension. Am J Physiol. 2011;300: H555-H564.
3. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95:4756-4761.
4. Raheja P, Price A, Wang Z, Arbique D, Huet BA, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60:319-325.
5. Leenen FH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension. 2001;37:981-984. (Pubitemid 32221623)
6. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol. 2006;290: H1706-H1712.
7. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, for the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL Study): A randomised, double-blind trial. Lancet. 2009;74:1840-1848.
8. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
9. Huang BS, Leenen FHH. The brain renin-Angiotensin-Aldosterone system: A major mechanism for sympathetic hyperactivity and LV remodeling and dysfunction post MI. Curr Heart Fail Rep. 2009;6:81-88.
10. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol. 2001;281:H2241-H2251.
11. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361-1366.
12. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension. 2010;55:1217-1223.